Cargando…
Report from a Consensus Conference on the treatment of Ménière’s disease with betahistine: rationale, methodology and results
Ménière’s disease is a disorder of the inner ear that causes vertigo, tinnitus, fullness and hearing loss. Although several treatments are available, the success rate is reported to be around 70%, similar to placebo. Betahistine, a weak H1 receptor agonist and an effective H3 receptor antagonist, is...
Autores principales: | CASANI, A.P., GUIDETTI, G., SCHOENHUBER, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pacini Editore Srl
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265668/ https://www.ncbi.nlm.nih.gov/pubmed/30498275 http://dx.doi.org/10.14639/0392-100X-2035 |
Ejemplares similares
-
Association of cinnarizine and betahistine in prophylactic therapy for Ménière's disease with and without migraine
por: Teggi, R., et al.
Publicado: (2014) -
Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of Ménière's disease: a 10-year experience
por: Monzani, D., et al.
Publicado: (2012) -
Good Clinical Approach: Delphi Consensus for the Use of Betahistine in Menière's Disease
por: Casani, Augusto Pietro, et al.
Publicado: (2018) -
Italian survey on benign paroxysmal positional
vertigo
por: Messina, A., et al.
Publicado: (2017) -
MR imaging of endolymphatic hydrops in Ménière’s disease: not all that glitters is gold
por: Conte, G., et al.
Publicado: (2018)